Zepto Life Technology has announced the launch of the FungiFlex Mold Panel, a plasma-based molecular diagnostic test now available through its CLIA-certified reference laboratory, expanding access to faster, noninvasive testing for patients at risk of invasive fungal infections (IFIs).
The FungiFlex Mold Panel detects cell-free DNA (cfDNA), small fragments of fungal DNA circulating in the bloodstream, from a single plasma sample and is designed to identify 14 clinically important mold species, including Aspergillus and Mucorales pathogens. The test delivers results in less than 24 hours from sample receipt. While initially offered as a reference laboratory test, the FungiFlex Mold Panel represents the initial offering of Zepto's targeted, rapid, and deployable liquid biopsy platform for infectious disease diagnostics.
A targeted, blood-based molecular approach enables earlier clinical insight without the need for invasive sampling.
The FungiFlex Mold Panel is intended for patients with symptoms of, or medical conditions predisposing them to, invasive fungal disease, including individuals undergoing transplantation or receiving immunosuppressive therapies. Samples are processed at Zepto Life Technology's CLIA-certified laboratory in St. Paul, Minnesota.
Visit Zepto Life Technology for more information
